-+ 0.00%
-+ 0.00%
-+ 0.00%

Telomir Pharmaceuticals closes acquisition of TELI, secures global rights to Telomir-1

PUBT·04/24/2026 13:03:13
Listen to the news
Telomir Pharmaceuticals closes acquisition of TELI, secures global rights to Telomir-1
  • Telomir Pharmaceuticals closed its acquisition of TELI Pharmaceuticals, securing global rights to Telomir-1 (Telomir-Zn).
  • TELI became wholly owned subsidiary, consolidating previously split North American and international rights under one structure.
  • Deal used stock-for-stock consideration, with former TELI shareholders receiving Telomir common stock subject to a six-month lock-up.
  • Transaction brought USD 1 million in funding at closing.
  • Former TELI shareholders may contribute up to USD 4 million tied to IND acceptance and Phase 1/2 trial initiation milestones.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telomir Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202604240900ACCESSWRNAPR_____1160674) on April 24, 2026, and is solely responsible for the information contained therein.